Biclonal Desmoid-Type Fibromatosis With Two Beta-Catenin Mutations: Evidence for the Recruitment of Normal Myofibroblasts

Sporadic aggressive fibromatosis, or desmoid-type fibromatosis, is characterized by oncogenic mutations in CTNNB1. The clonal cell is a myofibroblast-like cell, and it has been hypothesized that the recruitment of normal myofibroblasts could contribute significantly to the tumor. We describe a case in which a CTNNB1 p.T41A mutation was present at a mutant allele frequency of 30%, suggesting that a significant proportion of the tumor myofibroblasts may have been recruited from normal precursor pools. In addition, a small subclone with a p.S45F mutation (allele frequency of 2%) was identified in the tumor. This case provides additional evidence that myofibroblasts recruited by a tumor from a normal precursor pool contribute significantly to the tumor; such recruitment could impact response to treatment and long-term outcomes.

[1]  A. Lazar,et al.  Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  Marie J Parsons,et al.  WNT as a Driver and Dependency in Cancer. , 2021, Cancer discovery.

[3]  V. Endris,et al.  The majority of β-catenin mutations in colorectal cancer is homozygous , 2020, BMC Cancer.

[4]  Robin L. Jones,et al.  The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. , 2020, European journal of cancer.

[5]  S. Sleijfer,et al.  Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  T. Matsunobu,et al.  Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study. , 2019, Human pathology.

[7]  Sewoon Kim,et al.  Mutation Hotspots in the β-Catenin Gene: Lessons from the Human Cancer Genome Databases , 2019, Molecules and cells.

[8]  L. De Cecco,et al.  β‐Catenin in desmoid‐type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression , 2017, Molecular oncology.

[9]  F. Chibon,et al.  Adult desmoid tumors: biology, management and ongoing trials , 2017, Current opinion in oncology.

[10]  K. Skubitz.  Biology and Treatment of Aggressive Fibromatosis or Desmoid Tumor , 2017, Mayo Clinic proceedings.

[11]  S. Imbeaud,et al.  Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progression , 2016, Hepatology.

[12]  P. Hohenberger,et al.  Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01) , 2016, Annals of Surgical Oncology.

[13]  J. Gugenheim,et al.  Spatio-temporal genetic heterogeneity of CTNNB1 mutations in sporadic desmoid type fibromatosis lesions , 2016, Virchows Archiv.

[14]  Y. Ando,et al.  Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status , 2015, International Journal of Clinical Oncology.

[15]  C. Verhoef,et al.  Prognostic Value of CTNNB1 Gene Mutation in Primary Sporadic Aggressive Fibromatosis , 2015, Annals of Surgical Oncology.

[16]  N. Ishiguro,et al.  CTNNB1 S45F Mutation Predicts Poor Efficacy of Meloxicam Treatment for Desmoid Tumors: A Pilot Study , 2014, PloS one.

[17]  J. Koopmeiners,et al.  Expression of FAP, ADAM12, WISP1, and SOX11 is heterogeneous in aggressive fibromatosis and spatially relates to the histologic features of tumor activity , 2013, Cancer medicine.

[18]  S. Bonvalot,et al.  CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence , 2013, Cancer.

[19]  Andrew,et al.  β-Catenin mutation status and outcomes in sporadic desmoid tumors. , 2013, The oncologist.

[20]  J. Coindre,et al.  CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics , 2012, Modern Pathology.

[21]  S. Antonarakis,et al.  A single-nucleotide substitution mutator phenotype revealed by exome sequencing of human colon adenomas. , 2012, Cancer research.

[22]  P. Terrier,et al.  The treatment of desmoid tumors: a stepwise clinical approach. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  G. Eberl,et al.  Lineage tracing and genetic ablation of ADAM12+ perivascular cells identify a major source of profibrotic cells during acute tissue injury , 2012, Nature Medicine.

[24]  J. Blay,et al.  High frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management , 2010, British Journal of Cancer.

[25]  A. Lazar,et al.  Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. , 2008, The American journal of pathology.

[26]  Gunnar Westin,et al.  Stabilizing mutation of CTNNB1/beta-catenin and protein accumulation analyzed in a large series of parathyroid tumors of Swedish patients , 2008, Molecular Cancer.

[27]  A. Skubitz,et al.  Gene expression in aggressive fibromatosis. , 2004, The Journal of laboratory and clinical medicine.

[28]  William I. Weis,et al.  The Structure of the β-Catenin/E-Cadherin Complex and the Molecular Basis of Diverse Ligand Recognition by β-Catenin , 2001, Cell.

[29]  Y. Yuasa,et al.  β-Catenin and adenomatous polyposis coli (APC) mutations in adenomas from hereditary non-polyposis colorectal cancer patients , 2000 .

[30]  B. Alman,et al.  Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). , 1997, The American journal of pathology.

[31]  W. Gerald,et al.  Desmoid fibromatosis is a clonal process. , 1996, Human pathology.